I'm the former head of Pfizer R&D, and I'm deeply concerned about the future of biopharma. Here's why.
In 2006, I sat down with a young reporter from The New York Times, Alex Berenson, who was tasked with interviewing me about Pfizer's research and development prospects. It was a pivotal moment, as the pharmaceutical industry was facing a productivity slump. The Food and Drug Administration had approved 311 new medicines in the 1990s, but over the next decade, despite massive investments, only 235 approvals were granted. Industry skeptics were beginning to doubt the future.
But I had a different perspective. I believed the industry was on the brink of a major transformation. The groundbreaking advancements in understanding disease causes through the human genome project, coupled with the recognition of drugs beyond small molecules like antibodies and therapeutic vaccines, signaled a productivity surge. We were entering a new era of drug discovery, poised to revolutionize treatments for cancer, diabetes, and other debilitating conditions.
Berenson's article, titled "Dr. Optimistic," captured my viewpoint, but it also sparked debate. The article, accessible to STAT+ subscribers, highlighted the potential for a research dividend. However, it also raised questions about the industry's ability to sustain this momentum. Was I being too optimistic? The article's exclusivity to STAT+ subscribers further fueled the discussion, inviting readers to explore the complexities of biopharma's future.
Today, as a senior director at PureTech Health, my concerns remain. The biopharma industry faces challenges, but I firmly believe in the potential for innovation and breakthroughs. The key lies in embracing the transformative power of genomics and expanding our understanding of drug development. It's a journey that requires collaboration, investment, and a commitment to pushing the boundaries of what's possible.
